Ascendis Pharma A/S
Rating
Updated: Aug 25, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering...
Latest News
4 days ago · seekingalpha.com
Ascendis Pharma: Back To Full IndependenceAscendis Pharma faces negative sentiment after Novo returned TransCon rights, compounding prior partner exits and pipeline disappointments. Despite pipeline contraction, ASND's approved products—Skytrofa, Yorvipath, and Yuviwel—show robust growth, and Yorvipath net sales should exceed $1.1 billion this year. Yuviwel's strong U.S. launch and favorable BioMarin settlement provide freedom to operate.
5 days ago · seekingalpha.com
Ascendis Pharma A/S (ASND) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptAscendis Pharma A/S (ASND) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
6 days ago · benzinga.com
Why Is Ascendis Pharma Stock Trading Lower on Tuesday?Ascendis Pharma A/S (NASDAQ:ASND) shares are trading lower on Tuesday as investors digest news that the company will regain rights to certain TransCon technology-based programs and a share buyback.
6 days ago · globenewswire.com
Ascendis Announces Planned $400 Million Share Repurchase ProgramCOPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of the Company's ordinary shares (the Share Repurchase Program).
6 days ago · globenewswire.com
Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis- Ascendis to initiate multiple programs in metabolic and cardiovascular diseases, including obesity
14 days ago · globenewswire.com
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026COPENHAGEN, Denmark, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, the annual congress of the European Society for Paediatric Endocrinology (ESPE) being held September 8-10, 2026, in Marseille, France. Updates will include a podium presentation of the first sentinel cohort data from the pivotal reACHin Trial of TransCon CNP (navepegritide) in infants with achondroplasia aged 0 to
21 days ago · benzinga.com
Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On MondayU.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday.
25 days ago · benzinga.com
This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For ThursdayTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
1 month ago · globenewswire.com
Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration PatientsFirst patients dosed in OVERTURE, a Phase 1b/2a study evaluating EYC-0305, a potential long-acting anti-VEGF therapy designed for six-month or longer dosing intervals via standard intravitreal injection
1 month ago · seekingalpha.com
Ascendis Pharma A/S (ASND) Q2 2026 Earnings Call TranscriptAscendis Pharma A/S (ASND) Q2 2026 Earnings Call Transcript
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ASND